What is FEops?
Founded in 2009, FEops is at the forefront of transforming heart disease treatment through advanced digital tools. The company empowers physicians by enabling them to identify the right patients for specific treatments and utilize the most appropriate technologies at the optimal time. This precision-driven approach aims to significantly improve patient outcomes and streamline the application of medical technology in cardiology. FEops operates within the rapidly evolving digital health landscape, positioning itself as a key player in leveraging technology for better cardiac care.
How much funding has FEops raised?
FEops has raised a total of $12M across 3 funding rounds:
Series A
$1.5M
Series B
$7.2M
Debt
$3.3M
Series A (2015): $1.5M with participation from Capricorn Venture Partners and PMVenture
Series B (2017): $7.2M led by Capricorn Venture Partners, Valiance, and PMV
Debt (2022): $3.3M supported by The European Innovation Council
Key Investors in FEops
Capricorn Venture Partners
Capricorn Partners is an independent manager specializing in venture capital and growth capital for innovative technology companies, with a strong focus on Europe and a presence in digital and health sectors.
Valiance
Valiance Asset Management is a global investor focused on impactful technology businesses, aiming to provide life-changing opportunities and improve quality of life through strategic investments.
PMV
PMV is a financial partner supporting Flemish SMEs with tailored financing solutions, including investments in start-ups and scale-ups across various sectors like life sciences and clean tech.
What's next for FEops?
The recent major strategic investment signals a new phase of expansion and development for FEops. This capital infusion is expected to accelerate the company's product development, enhance its market reach, and further solidify its position in the global digital health market. With a clear focus on innovation and physician empowerment, FEops is poised to continue its trajectory of growth, driving advancements in how heart disease is managed and treated through cutting-edge digital solutions. The company's strategic backing suggests a focus on scaling operations and potentially exploring new therapeutic areas or technological integrations.
See full FEops company page
